Inhaler
Latest Novartis AG Patents:
- CD19 and CD22 chimeric antigen receptors and uses thereof
- Treatment of cancer using GFR alpha-4 chimeric antigen receptor
- Tricyclic AKR1C3 dependent KARS inhibitors
- Methods of treating HIV-HAART induced partial lipodystrophy with FGF21 protein variant FC fusion proteins
- Solid forms comprising an oxime ether compound, compositions and methods of use thereof
Description
Claims
The ornamental design for an inhaler, as shown and described.
Referenced Cited
U.S. Patent Documents
D518569 | April 4, 2006 | Nishibayashi et al. |
D527815 | September 5, 2006 | Nishibayashi et al. |
D527816 | September 5, 2006 | Nishibayashi et al. |
D527817 | September 5, 2006 | Ziegler et al. |
D528654 | September 19, 2006 | Nishibayashi et al. |
D613397 | April 6, 2010 | Nakao et al. |
D624641 | September 28, 2010 | Boclet |
D647195 | October 18, 2011 | Clarke et al. |
Patent History
Patent number: D697616
Type: Grant
Filed: Mar 8, 2013
Date of Patent: Jan 14, 2014
Assignee: Novartis AG (Basel)
Inventors: Mark Berry (Cambridge), Edward William Vernon-Harcourt (West Sussex)
Primary Examiner: Ian Simmons
Assistant Examiner: Richelle G Shelton
Application Number: 29/448,013
Type: Grant
Filed: Mar 8, 2013
Date of Patent: Jan 14, 2014
Assignee: Novartis AG (Basel)
Inventors: Mark Berry (Cambridge), Edward William Vernon-Harcourt (West Sussex)
Primary Examiner: Ian Simmons
Assistant Examiner: Richelle G Shelton
Application Number: 29/448,013
Classifications
Current U.S. Class:
Respirator, Vaporizer, Or Inhalation Tube (4) (D24/110)